Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Ann Rheum Dis · 2019 · PMC6579552 · PMID 30902820

Europe PMC DOI

hedged sentence

0.0765

closest p · 1.5× alpha

0.0765

boldest claim

The sentences

did not reach statistical significancep=0.0765so close (0.05 < p ≤ 0.1)

A reduction in the median percentage of circulating CD19+IgD−CD27+CD95+ B cells and CD19+IgD+CD27+CD95+ B cells from baseline was also observed for BI 655064 vs placebo, but the differences at week 12 did not reach statistical significance (–15.3% vs 2.3%; p=0.0765 and 16.8% vs –8.0%; p=0.0831, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.